Related Experiment Video
Updated: Sep 30, 2026
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
Published on: May 2, 2025
The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction
Paul Harrison1, M Robinson, R Liesner
1Haemostasis Research, Department of Haematology, University College Hospital, London, UK. paul.harrison@ndm.ox.ac.uk
Insights
The PFA-100 device effectively screens for platelet function disorders, including von Willebrand
Area of Science:
- Hematology
- Clinical Diagnostics
- Platelet Function Assays
Background:
- Platelet function disorders, including von Willebrand's disease (VWD), require accurate and efficient screening methods.
- The PFA-100 assay simulates in vitro high shear stress to assess platelet function.
Purpose of the Study:
- To evaluate the PFA-100 as a primary clinical screening tool for platelet dysfunction.
- To assess the sensitivity and specificity of the PFA-100 using diverse patient samples.
Main Methods:
- The PFA-100 test was conducted on 337 patients with various hemostatic defects using collagen/ADP (CADP) and collagen/epinephrine (CEPI) cartridges.
- Patient samples were compared against classical laboratory tests and von Willebrand factor levels to define normal platelet function.
Main Results:
- The PFA-100 demonstrated overall clinical sensitivity of 81% (CADP) and 86% (CEPI) for platelet abnormalities.
- Specificities were 82% (CADP) and 80% (CEPI). Combined use of cartridges resulted in 12% false positives and 6% false negatives.
- The assay effectively identified major defects like VWD but showed some false negatives in milder platelet disorders.
Conclusions:
- The PFA-100 is a valuable rapid screening tool for platelet dysfunction.
- Its use can enhance diagnostic efficiency and reduce costs for routine platelet function testing.
- The PFA-100 shows promise for widespread clinical application in diagnosing hemostatic defects.
Abstract:
The PFA-100 is a device that simulates high shear dependent platelet function in vitro and thus is particularly useful for screening for von Willebrand's disease (VWD). The aim of this study was to assess the overall potential of the PFA-100 as a primary clinical screening tool using the wide spectrum of clinical samples assessed for platelet function within our institution. The PFA-100 test was performed using both collagen/ADP (CADP) and collagen/epinephrine (CEPI) cartridges on samples from 337 patients with a wide variety of haemostatic defects. One hundred and eighty-two patients were defined as having normal platelet function based on classical laboratory tests and von Willebrand factor levels. The overall clinical sensitivity of the PFA-100 for platelet abnormalities (including VWD) was 81% for CADP and 86% for CEPI. The overall specificity was found to be 82% for CADP and 80% for CEPI. When utilizing both cartridges in combination (with both results either higher or lower than the upper cutoff of the normal ranges), the overall false positive and false negative rates were 12% and 6%, respectively. The PFA-100 proved to be sensitive in detecting classical defects by giving prolonged closure times in samples from patients with major platelet function defects (e.g. von Willebrand's disease, Glanzmann's thrombasthenia and Bernard Soulier syndrome). However, there were a small number of false negative results (6%) obtained with various milder platelet defects (e.g. Hermansky Pudlak syndrome, storage pool and release defects, type I VWD and macrothrombocytopenia). The PFA-100 test provides a useful rapid screening tool and should increase the efficiency and reduce the cost of the routine diagnosis of platelet dysfunction.
